Index -
P/E -
EPS (ttm) -1.45
Insider Own 0.20%
Shs Outstand 66.87M
Perf Week 5.52%
Market Cap 614.86M
Forward P/E -
EPS next Y -1.86
Insider Trans -53.88%
Shs Float 60.26M
Perf Month -2.33%
Income -96.30M
PEG -
EPS next Q -0.45
Inst Own 96.50%
Short Float / Ratio 7.71% / 4.65
Perf Quarter -31.22%
Sales 30.80M
P/S 19.96
EPS this Y 16.80%
Inst Trans 0.41%
Short Interest 4.65M
Perf Half Y -42.25%
Book/sh 2.64
P/B 3.33
EPS next Y -6.90%
ROA -37.40%
Target Price 29.12
Perf Year -34.30%
Cash/sh 2.44
P/C 3.60
EPS next 5Y -
ROE -46.40%
52W Range 5.77 - 18.96
Perf YTD -44.19%
Dividend -
P/FCF -
EPS past 5Y 11.80%
ROI -45.50%
52W High -53.64%
Beta 0.53
Dividend % -
Quick Ratio 10.10
Sales past 5Y 77.60%
Gross Margin 58.90%
52W Low 52.34%
ATR 0.45
Employees 105
Current Ratio 10.10
Sales Q/Q 66.70%
Oper. Margin -
RSI (14) 55.43
Volatility 5.52% 5.18%
Optionable Yes
Debt/Eq 0.00
EPS Q/Q -37.70%
Profit Margin -
Rel Volume 1.31
Prev Close 8.70
Shortable Yes
LT Debt/Eq 0.00
Earnings May 08 BMO
Payout -
Avg Volume 999.37K
Price 8.79
Recom 1.40
SMA20 5.24%
SMA50 2.24%
SMA200 -34.48%
Volume 1,309,197
Change 1.03%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-22 Initiated
Stifel
Buy
$29
Dec-01-22 Initiated
Goldman
Buy
$25
Oct-06-22 Initiated
BTIG Research
Buy
$32
Jul-23-21 Resumed
Jefferies
Buy
$27 → $32
Jun-15-21 Initiated
Piper Sandler
Overweight
$30
Apr-21-21 Initiated
H.C. Wainwright
Buy
$40
Oct-22-19 Upgrade
SVB Leerink
Mkt Perform → Outperform
Sep-06-19 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Jun-27-19 Downgrade
SVB Leerink
Outperform → Mkt Perform
May-06-19 Initiated
SVB Leerink
Outperform
$13
Mar-28-18 Resumed
Leerink Partners
Outperform
$52
Feb-09-18 Initiated
Guggenheim
Buy
$53
Jun-16-17 Initiated
Cantor Fitzgerald
Overweight
$50
Nov-29-16 Initiated
Leerink Partners
Outperform
$54
Sep-30-16 Initiated
JMP Securities
Mkt Outperform
Jun-10-16 Initiated
Guggenheim
Buy
$35
Nov-02-15 Initiated
Jefferies
Buy
$20
Nov-02-15 Initiated
Citigroup
Buy
Show Previous Ratings
Jun-02-23 07:00AM
May-18-23 01:50PM
May-10-23 06:04AM
May-08-23 11:55PM (Thomson Reuters StreetEvents) -6.46%
08:15AM
07:08AM
Loading…
07:08AM
07:00AM
May-05-23 06:49AM
May-02-23 07:01AM
Apr-27-23 04:35AM
Apr-24-23 02:37PM
Apr-04-23 07:40AM
Mar-27-23 07:00AM
Mar-10-23 11:34AM (American City Business Journals)
Mar-06-23 03:59PM
02:32PM
Loading…
02:32PM
01:03PM
11:50AM
07:00AM
Feb-23-23 08:35AM
07:00AM
Feb-22-23 06:01AM
Feb-09-23 04:01PM
Jan-06-23 07:01AM
Nov-29-22 07:00AM
Nov-26-22 01:39PM (American City Business Journals)
Nov-22-22 04:01PM
Nov-16-22 12:10PM
Nov-10-22 04:01PM
Nov-08-22 08:25AM
07:00AM
Loading…
07:00AM
Oct-26-22 06:44AM
Sep-27-22 07:00AM
Sep-15-22 06:46AM
Aug-30-22 07:00AM
Aug-25-22 07:00AM
Aug-05-22 07:59AM
Aug-03-22 08:25AM
07:00AM
Aug-01-22 07:00AM
Jul-15-22 12:00PM
Jul-08-22 09:40AM
Jul-01-22 09:36AM (American City Business Journals)
Jun-27-22 07:00AM
Jun-22-22 09:40AM
Jun-20-22 08:20AM
Jun-13-22 09:55AM
Jun-06-22 09:40AM
Jun-01-22 04:01PM
May-27-22 09:55AM
May-17-22 11:53AM
May-16-22 07:00AM
May-10-22 08:15AM
07:00AM
May-04-22 07:35PM
May-03-22 07:00AM
May-02-22 06:10AM
Apr-13-22 12:17AM
Feb-24-22 08:55AM
07:00AM
Feb-21-22 04:34AM
Feb-17-22 03:03PM
Feb-06-22 04:33PM
Feb-02-22 07:00AM
Feb-01-22 04:01PM
Jan-11-22 04:01PM
Dec-27-21 07:00AM
Dec-20-21 05:21PM
Dec-08-21 11:59AM
Dec-03-21 07:00AM
Nov-23-21 04:13AM
Nov-18-21 04:01PM
Nov-03-21 07:00AM
Nov-02-21 08:25AM
07:00AM
Oct-27-21 03:03PM
Oct-12-21 07:16PM
Sep-29-21 08:47AM
Sep-20-21 08:00AM
Aug-26-21 04:01PM
Aug-25-21 06:16AM
Aug-05-21 10:58AM
07:00AM
Jul-30-21 03:00PM
Jul-08-21 07:00AM
Jul-06-21 11:49AM
10:13AM
Jun-09-21 07:55PM
11:00AM
Jun-08-21 04:15PM
07:46AM
07:00AM
May-18-21 01:25AM
May-17-21 07:00AM
May-07-21 08:35AM
07:00AM
Apr-29-21 05:02PM
Apr-26-21 01:39AM
Mar-15-21 07:00AM
Feb-25-21 07:00AM
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Manion Douglas J. Pres and CEO Mar 17 Buy 7.86 6,300 49,532 12,800 Mar 17 05:03 PM Manion Douglas J. Pres and CEO Mar 09 Buy 7.74 6,500 50,278 6,500 Mar 09 05:56 PM Walker Neal Director Mar 03 Sale 12.63 30,240 382,070 1,273,202 Mar 03 08:37 PM Monahan Joseph Chief Scientific Officer Mar 03 Sale 12.63 16,037 202,615 147,724 Mar 03 08:12 PM Balthaser Kevin Chief Financial Officer Mar 03 Sale 12.63 894 11,290 5,256 Mar 03 08:09 PM Walker Neal Director Mar 02 Sale 12.37 29,000 358,588 1,285,188 Mar 03 08:37 PM Monahan Joseph Chief Scientific Officer Mar 02 Sale 12.37 14,800 183,024 151,261 Mar 03 08:12 PM Balthaser Kevin Chief Financial Officer Mar 02 Sale 12.29 1,000 12,289 4,650 Mar 03 08:09 PM Monahan Joseph Chief Scientific Officer Feb 15 Sale 13.06 5,000 65,310 91,386 Feb 17 04:34 PM Loerop James Chief Business Officer Feb 08 Sale 13.89 4,267 59,272 6,983 Feb 10 04:55 PM Walker Neal Director Feb 02 Sale 16.25 5,000 81,248 1,175,763 Feb 03 05:09 PM Walker Neal Director Feb 01 Sale 16.75 25,000 418,675 1,180,763 Feb 03 05:09 PM Walker Neal Director Jan 04 Sale 14.89 15,000 223,342 1,205,763 Jan 04 06:20 PM Walker Neal Director Jan 03 Sale 15.25 25,000 381,213 1,220,763 Jan 04 06:20 PM Monahan Joseph Chief Scientific Officer Dec 15 Sale 15.88 5,000 79,412 96,386 Dec 16 04:57 PM SCHIFF ANDREW N Director Nov 14 Sale 17.08 1,371 23,417 434,455 Nov 14 04:51 PM SCHIFF ANDREW N Director Nov 11 Sale 17.06 41,160 702,177 435,826 Nov 14 04:51 PM SCHIFF ANDREW N Director Nov 10 Sale 17.02 11,395 193,995 476,986 Nov 14 04:51 PM SCHIFF ANDREW N Director Oct 26 Sale 17.00 14,540 247,253 488,381 Oct 26 07:09 PM SCHIFF ANDREW N Director Oct 25 Sale 17.02 12,018 204,516 502,921 Oct 26 07:09 PM SCHIFF ANDREW N Director Oct 24 Sale 17.01 14,616 248,586 514,939 Oct 26 07:09 PM SCHIFF ANDREW N Director Oct 18 Sale 16.89 32,093 542,022 529,555 Oct 19 04:49 PM SCHIFF ANDREW N Director Oct 17 Sale 16.05 19,944 320,087 561,648 Oct 19 04:49 PM Monahan Joseph Chief Scientific Officer Oct 17 Sale 15.98 5,000 79,908 101,386 Oct 19 04:45 PM SCHIFF ANDREW N Director Oct 07 Sale 16.16 7,324 118,349 581,592 Oct 11 04:35 PM SCHIFF ANDREW N Director Oct 06 Sale 16.54 37,839 625,744 588,916 Oct 06 05:58 PM SCHIFF ANDREW N Director Oct 04 Sale 16.01 7,700 123,259 626,755 Oct 06 05:58 PM SCHIFF ANDREW N Director Jun 17 Sale 15.14 19,565 296,269 0 Jun 21 04:57 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite